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INTRODUCTION 
 
HIV is driving TB epidemic in many countries, especially in 
sub-saharan Africa and increasingly, in Asia and South America. TB in 
populations with high HIV prevalence is a leading cause of morbidity 
and mortality. 
 
Children who are HIV infected have a higher risk of progression 
after primary infection. Children born to HIV positive parents who are 
not infected with TB themselves, are also at higher risk of acquiring 
TB because of exposure. The source of transmission of TB to a child is 
usually an adult with sputum-smear positive PTB. Cases of TB in 
children represent between 10% to 20% of all TB cases.  
 
Extrapulmonary TB manifestations are Lymphadenopathy, 
Pleural effusion, Miliary TB, TB meningitis, TB Abdomen, 
Disseminated TB, Potts Spine. 
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AIM OF THE STUDY 
 
1. To evaluate the clinical, bacteriological and radiological pattern 
of TB in HIV seropositive children in correlation with CD4 
count. 
 
2. To find out the trends of TB infection in HIV seropositive 
children in GMKMCH, Salem. 
 
3. To find out the prevalence of TB among HIV seropositive 
children in our hospital. 
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REVIEW OF LITERATURE 
 
TUBERCULOSIS: An overview 
Tuberculosis has been present in humans since antiquity, as the 
origin of the disease are in the first demonstration of cattle (which also 
gave human viral pores). Skeletal remains show prehistoric humans 
(4000BC) had TB1 and tubercular decay has been found in the spines 
of Egyptian mummies from 3000-2400BC2. There were references to 
TB in India around 2000 BC and indications of lung scarring identical 
to that of modern day TB sufferers in preserved bodies (such as 
mummies) suggests that TB was present in the Americans from about 
2000 BC. Phthisis is a Greek term for consumption. Around 460 BC, 
Hippocrates identified phthisis as the most widespread disease of the 
times which was almost always fatal3. 
Due to the variety of the symptoms, TB was not identified as a 
single disease until the 1820’s and was not named tuberculosis until 
1839 by JL Schonlein4. The bacillus causing tuberculosis, 
Mycobacterium tuberculosis, was identified and described on March 
24, 1882 by Robert Koch. He received the Nobel Prize in physiology 
(or) medicine in 1905 for his discovery5.  
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The other names for tuberculosis are:  
TB (short for tuberculosis and also for Tubercle Bacillus). 
Consumption (TB seemed to consume people from within with 
its symptoms of bloody cough, fever, pallor and long relentless 
wasting). 
Wasting disease. 
King’s evil. 
White Plague (TB sufferers appear markedly pale)  
Phthisis (Greek for consumption) and phthisis pulmonalis. 
Miliary TB (X-ray lesions look like millet seeds) 6. 
Koch’s disease named after Robert Koch who discovered the 
tuberculosis bacilli7. 
 
PATHOGENESIS: 
While only 10% of TB infection progresses to TB disease8, if 
untreated the death rate is 51%9.The primary complex of tuberculosis 
includes local infection at the portal of entry and the regional lymph 
nodes. TB infection begins when the MTB bacilli reach the pulmonary 
alveoli, infecting alveolar macrophages 8, 10, where the mycobacteria 
replicate. The primary site of infection in the lungs is called the Ghon 
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focus, which is the combination of a parenchymal pulmonary lesion 
and a corresponding lymph node site. 
The tubercle bacilli are carried to most tissues of the body 
through the blood and lymphatic vessels to the more distant tissues and 
organs where TB disease could potentially develop: lung apices, 
peripheral lymph nodes, kidneys, brain and bone 8,11 . 
Tuberculosis is classified as one of the granulomatous inflammatory 
conditions. Macrophages, T lymphocytes, B lymphocytes and fibroblasts 
are among the cells that aggregate to form a granuloma, with lymphocytes 
surrounding infected macrophages. The granuloma functions not only to 
prevent dissemination of mycobacteria, but also provides a local 
environment for communication of cells of the immune system. Within 
the granuloma, T lymphocytes (CD4 +) secrete a cytokine such as 
interferon gamma, which activates macrophages to destroy the bacteria 
with which they are infected12, making them better able to fight infection. 
T lymphocytes (CD8 +) can also directly kill infected cells by secreting 
perforin and granulysin13. 
Importantly, bacteria are not eliminated within the granuloma, but 
can become dormant resulting in a latent infection8. Latent infection can 
be diagnosed by tuberculin skin test, which yields a delayed 
hypersensitivity type response to purified protein derivatives of M. 
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tuberculosis in an infected person.Another feature of the granulomas of 
human tuberculosis is the development of cell death, also called necrosis, 
in the centre of tubercles. To the naked eye this has the texture of soft 
white cheese and was termed caseous necrosis14.  
If TB bacteria gain entry to the blood stream from an area of 
tissue damage they spread through the body and set up myriad foci of 
infection, all appearing as tiny white tubercles in the tissues. This is 
called as miliary tuberculosis and has a high case fatality. 
  
PROGRESSION: 
In children in whom TB bacilli overcome the immune system 
defenses and begin to multiply, there is progression from TB infection 
to TB disease. This may occur soon after infection (primary TB 
disease-1 to 5%) or many years after infection (post primary TB, 
secondary TB, reactivation TB disease of dormant bacilli-5 to 9%). 
About five percent of infected persons will develop TB in first two 
years and another five percent will develop disease later in life. In 
another words about 10% of infected persons with normal immune 
systems will develop TB disease in their lifetime8.  
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Some medical conditions increase the risk of progression to TB 
disease. In HIV infected children the rate of tuberculosis disease is 30 
times higher than in non HIV infected children. Other conditions such 
as prolonged corticosteroid therapy, immunosuppressive therapy, 
leukemia, Hodgkins disease, end stage renal disease, recent TB 
infection, (within two years, or history of inadequately treated 
TB),chest Xray suggestive of previous TB (fibrotic lesion and 
nodules),chronic malabsorption syndrome or low body weight (10%or 
more below the ideal). 
Primary complex includes the parenchymal pulmonary focus 
and the regional lymph nodes15. About 70% of pulmonary foci are 
subpleural and localized pleurisy is common. The hallmark of primary 
tuberculosis is the relatively large size of regional lymphadenitis 
compared with the relatively small size of initial lung focus 
Children may have lobar pneumonia without impressive hilar 
lymphadenopathy. If primary infection is destructive , liquefaction of 
the lung parenchyma can lead to the formation of a thin walled primary 
tuberculosis cavity. Rarely, bullous tuberculous lesions can occur in 
lungs and lead to pneumothorax if they rupture15 Erosion of a 
parenchymal focus of tuberculosis into a blood or lymphatic vessel 
may result in dissemination of the bacilli and a miliary pattern. 
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No clinical disease 
Positive tuberculosis 
(usual outcome:90%of cases) 
 
 
PRIMARY  
COMPLEX  
 
 
 
 
 
      
Disseminated disease  
Lymphadenopathy (usually cervical) 
Meningitis 
Pericarditis  
Miliary disease 
TB Spine 
Hypersensitivity reactions (eg) Erythema  
nodosum,  
Phlyctenular conjunctivitis  
Dactylitis. 
Primary and pleural complication (eg)TB 
pneumonia, Hyper inflation and Collapse  
Pleural effusion Consolidation. 
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More than 50% of infants and children with radiologically 
moderate to severe pulmonary TB have no physical findings and are 
discovered only by contact tracing .Non productive cough and dyspnea 
are the most common symptoms. Systemic complaints such as fever, 
night sweats, anorexia and decreased activity occur less often . 
 
Older children and adolescents with reactivation tuberculosis are 
more likely to experience fever, anorexia, malaise, weight loss, night 
sweats, productive cough, hemoptysis and chest pain than children 
with primary pulmonary TB. 
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POST-PRIMARY TB 
PULMONARY TUBERCULOSIS 
 (eg)    Cavities 
  Upper lobe infiltrates 
  Fibrosis 
  Progressive pneumonia 
  Endobronchial  
   
EXTRAPULMONARY TB 
COMMON LESS COMMON 
Pleural effusion Empyema 
Lymphadenopathy 
(usually cervical) 
Kidney 
Central nervous system 
(Meningitis,tuberculoma) 
Adrenal gland 
Pericarditis (Effusion/pericarditis) 
Skin  (lupus vulgaris, 
tuberculids, miliary) 
Gastrointestinal 
(ileocaecal, peritoneal) 
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DIAGNOSIS: 
A complete evaluation of TB includes a history of contact with 
adult TB, a physical examination, clinical features, a tuberculin skin 
test, a chest x-ray, serological test and microbiological smears and 
cultures. The interpretation of the tuberculin skin test depends upon the 
persons risk factors for infection and progression to TB disease, such 
as exposure to other cases of TB or immunosupression16 .Tuberculin 
tests have the disadvantage in that they may produce false negatives, 
especially when the patient is co-morbid with malnutrition, sarcoidosis, 
Hodgkins lymphoma or most notably active tuberculosis disease8. New 
TB tests are being developed that offer the hope of cheap ,fast and 
more accurate TB testing. These include PCR detection of bacterial 
DNA ,and assays to detect the release of interferon gamma in response 
to mycobacterial proteins such as ESAT-617.These are not affected by 
immunization or environment mycobacteria, so generate fewer false 
positive results18. The development of a rapid and inexpensive 
diagnostic test would be particularly valuable in the developing 
world19. 
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HIV-AN INTRODUCTION 
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Ever since the first description of AIDS in 1981,researchers have 
identified two types of HIV. HIV-1 Subtype C is the predominant type 
worldwide. HIV-2 occurs mostly in West Africa and occasional 
infections have occurred in Africa, Europe, Asia, and Latin America. 
Both types cause AIDS and the routes of transmission are the same. 
 
EPIDEMIOLOGY 
The WHO estimated that more than 39 million persons 
worldwide were living with HIV infection at the end of 2008, 
including 2.2 million children < 15 years of age15. Sub-saharan Africa 
accounts for the fastest growing epidemic, with almost 90% of worlds 
total population of HIV infected children. India and Thailand dominate 
the epidemic in Southeast Asia. 
 
Virtually all HIV infections in children < 12 years of age are the 
result of vertical transmission from an HIV infected mother. A 
vanishing minority of children are infected by contaminated blood 
products and or clotting factors. The risk of transmission without 
Breast Feeding is 20-25%, with Breast Feeding for 6 months is 25-30% 
and the risk increases to 30-35% with prolonged Breast feeding for  
18-24 months.15 
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The risk of transmission can be reduced to 1% by: 
a) ARV prophylaxis to women during pregnancy/labour and to the 
infant in first week. 
b) Elective caesarean section – prior to onset of labour and rupture 
of membranes 
c) Complete avoidance of Breast feeding. 
The clinical consequences of HIV infection are due to the ability 
of this virus to disarm the host immune system, a process that occurs 
by virtue of the fact that the primary target for the virus is the helper 
induced subset of lymphocytes. This lymphocyte subset, defined by its 
surface expression of the CD4 molecule, acts as the pivotal 
orchestrator of a myriad of immune functions. HIV infection can 
therefore be considered a disease of the immune system, characterized 
by the progressive loss of CD4 + lymphocytes, with ultimately total 
consequences for the infected host8. 
Despite the immunosuppression induced by HIV, a number of 
specific immunologic defences against the virus are generated in 
infected individuals and may contribute to the long asymptomatic 
phase following infection by keeping the virus atleast partially 
contained. The hallmark of HIV infection is progressive depletion of 
the CD4 helper inducer subset of lymphocytes. Because of the central 
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role of these cells in immunologic functioning, the clinical disease 
manifestation of immunosuppression and susceptibility to 
opportunistic infections and neoplasms are not surprising. The 
immunologic deficit associated with HIV infection are wide spread and 
involve numerous interdependent effector arms of the immune system, 
including both cellular and humoral elements. 
Of all the opportunistic infections in persons infected with HIV 
virus, tuberculosis remains the commonest20. HIV probably increases 
the susceptibility to primary infection with M-tuberculosis, as well as 
to reactivation of TB infection due to depressed CMI21,22. HIV 
increases the risk of progression of M-tuberculosis infection to TB 
disease. This risk increases with increasing immunosuppression. HIV 
increases not only the risk but also the rate of progression of recent or 
latent M-tuberculosis infection to disease.  
WHO staging system for HIV infection and related disease in 
children younger than 13 years23,24.  
Two Classifications 
i) WHO Classification – Symptomatic HIV divided into four 
stages based on the severity of the symptoms. 
ii) CDC Classification – Clinical classification and immunological 
classification based on CD4. 
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Revised WHO Clinical Staging of HIV/AIDS for Infants and 
Children with Confirmed HIV infection (> 18 months of age – HIV 
Antibody Test Positive, < 18 months of age – Virologic Test 
Positive)23 
 
CLINICAL STAGE 1 (AYSMPTOMATIC) 
¾ Asymptomatic 
¾ Persistent generalized lymphadenopathy 
CLINICAL STAGE 2 (MILD) 
¾ Unexplained persistent hepatosplenomegaly 
¾ Papular pruritic eruptions 
¾ Extensive wart virus infection 
¾ Extensive molluscum contagiosum 
¾ Fungal nail infections 
¾ Recurrent oral ulcerations 
¾ Unexplained persistent parotid enlargement  
¾ Linear gingival erythema 
¾ Herpes zoster 
¾ Recurrent or chronic upper respiratory tract infections (otitis media, 
otorrhoea, sinusitis, tonsillitis) 
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CLINICAL STAGE 3 (ADVANCED) 
¾ Unexplained moderated malnutrition not adequately responding to 
standard therapy 
¾ Unexplained persistent diarrhea (14 days or more) 
¾ Unexplained persistent fever (above 37.5°C intermittent or 
constant, for longer than one month) 
¾ Persistent oral candidiasis (after first 6-8 weeks of life) 
¾ Oral hairy leukoplakia  
¾ Acute necrotizing ulcerative gingivitis/periodontitis 
¾ Lymph node TB 
¾ Pulmonary TB 
¾ Severe recurrent bacterial pneumonia  
¾ Symptomatic lymphoid interstitial pneumonitis 
¾ Chronic HIV – associated lung disease including bronchiectasis  
¾ Unexplained anemia (<8g/dl), neutropenia (<0.5x109/L3 ) or chronic 
thrombocytopenia (<50 x 109/L3 ) 
CLINICAL STAGE 4 (SEVERE) 
¾ Unexplained severe wasting, stunting or severe malnutrition not 
responding to standard therapy 
¾ Pneumocystis pneumonia  
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¾ Recurrent severe bacterial infections (e.g. empyema, pyomyositis, 
bone or joint infection, meningitis, but excluding pneumonia) 
¾ Chronic herpes simplex infection; (orolabial or cutaneous of more 
than one month’s duration or visceral at any site) 
¾ Extra pulmonary TB 
¾ Kaposi’s sarcoma 
¾ Oesophageal candidiasis (or candidiasis of trachea, bronchi or 
lungs) 
¾ Central nervous system toxoplasmosis (after one month of life) 
¾ HIV encephalopathy 
¾ Cytomegalovirus infection: retinitis or CMV infection affecting 
another organ, with onset at age over 1 month. 
¾ Extra pulmonary cryptococcosis (including meningitis) 
¾ Disseminated endemic mycosis (extrapulmonary histoplasmosis, 
coccidiomycosis 
¾ Chronic cryptosporidiosis 
¾ Chronic isosporiasis 
¾ Disseminated non-tuberculous mycobacteria infection 
¾ Cerebral or B cell non-Hodgkin lymphoma 
¾ Progressive multifocal leukoencephalopathy 
¾ Symptomatic HIV – associated nephropathy or HIV – associated 
cardiomyopathy 
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IMMUNOLOGICAL CLASSIFICATION BASED ON CD423 
Immunologic 
Definitions 
< 12 months 1-5 years 6-12 years 
µL % µL % µL % 
No evidence of 
suppression 
≥1500 ≥25 ≥1000 ≥25 ≥500 ≥25 
Evidence of 
moderate 
suppression 
750-1499 15-24 500-999 15-24 200-499 15-24 
Severe suppression <750 <15 <500 <15 <200 <15 
 
WHO case definitions for AIDS in children where HIV testing 
facilities are not available. 
 
MAJOR SIGNS: 
¾ Weight loss > 10% of body weight or failure to thrive 
¾ Chronic diarrhea (> one month) 
¾ Prolonged fever (> one month) 
¾ Severe or repeated pneumonia 
 
MINOR SIGNS: 
¾ Generalised lymphadenopathy  
¾ Oro – Pharyngeal candidiasis 
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¾ Repeated common infections (otitis, pharyngitis etc.,) 
¾ Generalised dermatitis 
¾ Confirmed maternal HIV infection. 
 
Pediatric AIDS is suspected in an infant or child presenting with 
atleast two major signs associated with atleast two minor signs in the 
absence of known cases of immunosuppression. 
These definitions detect the presence of symptomatic AIDS and 
not HIV infection itself and are confounded by malnutrition, diarrheal 
diseases and tuberculosis. 
 
PRACTICAL POINT: 
The term AIDS is used for epidemiological surveillance, not for 
clinical case. For patients with TB, persistent cough for more than one 
month should not be considered as a minor sign. 
Picture showing estimated HIV & TB coinfection in India25  
 
 
 
 
 
TB 
20 Million 
HIV 
 & TB  
2 
Million 
HIV 
5.1 Million 
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Features 
Stage of HIV Infection 
Early Late 
Clinical 
Presentation 
Often resembles 
post primary TB 
Often resembles primary 
TB; Extra pulmonary TB 
common 
Sputum smear 
result 
Often positive Often negative 
CXR 
Often shows 
cavities 
Atypical often infiltrates, 
Lower lobe lesions or 
intrathoracic lymphnodes 
 
EPIDEMIOLOGY: 
About a third of the HIV positive population worldwide is co-
infected with M-tuberculosis. This accounts to about 14 million people 
worldwide. Globally, 9% of all tuberculosis cases in adults are 
attributable to HIV26. Studies from sub-saharan Africa have recorded 
HIV seroprevalance rates of 50 - 70% in patients with tuberculosis. In 
Asia, where the HIV epidemic is still at early stage, the rate of HIV 
infection in TB patient has been lower. 
 
A HIV positive person infected with M-tuberculosis has a 50-
60% lifetime risk of developing TB disease as compared to an HIV 
negative person who has only a 10% risk.  
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Using estimates of prevalence of TB and HIV in various regions, 
It has been observed that by mid-1994 there were 5.6 million persons 
co-infected with HIV and TB worldwide, more than 1.15 million of 
these live in South-east Asia (including India)27. The proportion of 
HIV-attributable tuberculosis death will increase from 4.6% to 14.2%. 
 
In India the rates of HIV-tuberculosis co-infection is steadily 
increasing. In Pune the prevalence of HIV infection among 
tuberculosis patients increased from 3.2% in 1991 to 20.1%28. Most 
available data on HIV and TB is from adults. Disease in children 
follows progressions of primary infection. It is estimated that 
worldwide there will be over 56,000 cases of HIV attributable 
tuberculosis annually in children by 200629. A study from Mumbai 
showed a prevalence of HIV of 18% among children with CNS 
tuberculosis or miliary tuberculosis; the prevalence HIV seropositivity 
among children with chronic diarrhea in same study was 24%30. 
 
TUBERCULOSIS IN HIV INFECTION: 
HIV has had as substantial effect on the incidence clinical 
manifestations, treatment and outcome of TB. Globally, HIV and TB 
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are the 2 leading infectious causes of death.People who are infected 
with HIV are at increased risk of contracting TB.  
 
Co-infection with these pathogens can be particularly 
devastating, especially in the developing world, where the burden of 
disease is high and access to effective therapy in low. Among infection 
associated with HIV, TB is unique in that it may be transmitted to 
immunocompetent persons via the respiratory route, and is easily 
treatable once identified, may occur in early stage HIV- disease and is 
preventable with drug therapy. However, multidrug resistance 
tuberculosis is a potentially serious problem, even though its incidence 
has declined because of the use of directly observed therapy and other 
improved practices31. 
 
TB is a major opportunistic infection in HIV-infected patients 
often representing their AIDS defining illness and the first indication 
of immunodeficiency. Epidemiology, clinical manifestations and 
management of TB are altered in HIV-infected patients. 
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IMPACT OF HIV ON TB 
HIV is the most significant risk factor for progression from sub-
clinical infection with mycobacterium tuberculosis to active TB.22 
 
However, when a person is dually infected with HIV and M-
tuberculosis, the risk of developing TB significantly increases from 
10% in a lifetime to 5-15% per year31.  
 
HIV infected children are at markedly increased risk for primary 
or reactivation tuberculosis and for second episodes of tuberculosis 
from exogenous reinfection32.  
 
The lifetime risk for progression to active TB among HIV-
negative persons likely infected with M-tuberculosis is estimated at 
10%. In contrast, among HIV infected children the risk for progression 
to active disease is approximately 10% per year, and the immediate 
risk for progressive primary disease after recent infection with M-
tuberculosis approaches 40%33. 
 
This interaction between TB and HIV accounts for much of the 
recent global resurgance in TB of late, however HIV infection does not 
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increase the infectiousness of persons with active TB. The introduction 
of potent combination Anti-retroviral therapy in developing world, 
which has dramatically decreased the risk for opportunities infections 
and death among HIV infected children, has also decreased the risk for 
developing active TB and the risk for death among HIV infected 
persons who develop active TB. 
 
Children born to HIV infected mother but who are not infected, 
are also at higher risk of acquiring tuberculosis because of the 
increased risk of exposure to tuberculosis from their parents. It is 
estimated that tuberculosis rate in the first four years of life among 
children born to HIV infected mothers is 10 times higher than in non 
HIV infected and 30 times higher in HIV infected children as 
compared to other children. 
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PATHOGENESIS: 
Tuberculosis can develop through progression of recently 
acquired infection (primary disease), reactivation of latent infection, or 
exogenous reinfection. 
 
  Infection with M-tuberculosis can occur when a child is exposed 
to an infectious case of TB particles (<5 cm in size) containing the 
tubercle bacilli. If the bacilli reach the pulmonary alveoli, they may be 
ingested by alveoli macrophages the first line of defence against       
M-tuberculosis. Surviving tubercle bacilli multiply within the 
macrophage and eventually undergo hematogenous spread to other 
areas of the body. 
 
After ingestion, alveoli macrophages present the mycobacterial 
antigens to CD4 + T cells. This results in the release of interferon 
gamma (IFN γ) which in turn activities macrophages to control the 
mycobacterial infection. However the activated macrophages also 
release interleukin – 1 which enhances HIV replication. Mycobacteria 
also enhance HIV replication by inducing nuclear factor kappa-B, the 
cellular factors that bends the promote region of HIV34,35. 
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Susceptibility to TB is related to the pattern of cytokines 
produced by T lymphocytes. CD4 + lymphocytes which produce 
interferon-γ are central to antimycobacterial immune defenses and fatal 
mycobacterial disease develops in children who lack the interferon γ 
receptor. In contrast to CD4+lymphocytes, CD8 + lymphocytes, which 
produce interleukin -4 and interleukin -10 do not contribute to anti 
mycobacterial immunity. When peripheral blood lymphocytes from 
HIV infected patients with tuberculosis are exposed to M-tuberculosis 
in vitro, they produce less interferon–γ but similar amounts of 
interleukin-4 and interleukin-10, as compared with lymphocytes from 
HIV- negative patients with tuberculosis. These findings suggest that 
the reduced CD4 response in HIV-infected patients contributes to their 
susceptibility to TB. 
 
The hallmark of HIV infection is progressive deterioration and 
depletion of CD4cells, coupled with defects in macrophage and 
monocyte function. There is evidence that the immune response in 
patients with TB might enhance HIV viral replication and accelerate 
the natural progression of HIV infection 36.  
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TUBERCULOSIS AND THE COURSE OF HIV INFECTION: 
Exposure of alveolar macrophages and lymphocytes from HIV 
infected patients to M.Tuberculosis in vitro upregulates retroviral 
replication34,35. TB has been associated with a 5 to 160 fold increase in 
HIV viral replication, which may decrease after successful TB 
treatment. 
 
Pleural fluid from patients with tuberculosis increases HIV 
replication in activated lymphocytes and in HIV-infected patients with 
pulmonary tuberculosis, the concentrations of retroviral RNA in 
bronchoalveolar lavage fluid are highest in areas of tuberculous 
involvement37.M.Tuberculosis probably increases HIV replication by 
inducing macrophages to produce tumor necrosis factor α, interleukin-
1 and interleukin-6 38,39. 
 
CLINICAL MANIFESTATIONS OF TB IN HIV: 
Unlike other opportunistic infections, TB can occur in persons 
with early –stage HIV infection (CD4 count >300/cubic mm). Clinical 
and radiological manifestations of TB are similar to those seen in non 
HIV infected persons (37,40). 
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Children are less likely to present with extrapulmonary disease 
at this stage of HIV infection. Because of the increased virulence in 
immunocompetent hosts of M.Tuberculosis compared with other 
opportunistic infections, tuberculosis can occur early in the course of 
HIV infection. In several studies of HIV infected children with 
pulmonary tuberculosis, the median CD4 T-cell count was >300 
cells/cubic mm. 
 
Studies have shown that 88-92% of HIV infected persons with 
TB had only pulmonary involvement, whereas 0.6to3%had both 
pulmonary and extrapulmonary and 8to12% had only extrapulmonary 
involvement37. Of those with extrapulmonary involvement 85% had 
lymphadenopathy (mainly cervical) 37.  
 
Miliary tuberculosis was uncommon and found in only 1.7% of 
HIV children with TB37. Though many HIV infected patients have 
typical clinical and radiological manifestations of tuberculosis, atypical 
presentations do occur frequently, especially in those with low CD4 
counts. Thus cavitatory upper lobe tuberculosis is more common with 
those with CD4 counts >200/cubic mm, whereas hilar/mediastinal 
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adenopathy and diffuse pulmonary infiltrates (without cavitation) are 
more common in those with CD4 counts <200/cubic mm. 
 
Typical symptoms include fever weight loss, cough of several 
weeks duration and failure of pulmonary signs and symptoms to 
subside despite adequate antibiotic therapy. Chest radiographs 
demonstrate the presence of lobar infiltrates with or without hilar 
adenopathy and diffuse infiltrates.In children with advanced HIV 
disease, TB may present atypical and common extrapulmonary 
manifestations were lymphadenopathy, pleural effusion, TB abdomen, 
TB meningitis and miliary tuberculosis42.  
 
The clinical feature of TB meningitis in children who are 
seropositive for HIV are not siginificantly different from those in 
seronegative children. However ventriculomegaly, gyral enhancement 
and cortical atrophy on CT scan are more common in HIV seropositive 
children43. Also,mortality and the incidence of severe neurological 
sequelae are more common in HIV seropositive children. Co-existing 
HIV encephalopathy and diminished immune function may account for 
poorer prognosis43.  
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RADIOGRAPHIC FINDINGS: 
The chest radiograph is the cornerstone of diagnosis for 
pulmonary tuberculosis. Upper lobe infiltrates and cavities are the 
typical findings in reactivation tuberculosis, whereas intrathoracic 
lymphadenopathy and lower lobe disease are seen in primary 
tuberculosis. In HIV-infected children with CD4 T cell counts >200/ 
cubic mm the radiographic pattern tends to be one of the reactivation 
disease with upper lobe infiltrates with or without cavities.  
 
In HIV-infected persons with a greater degree of 
immunosuppression (e.g. CD4 T-cell count < 200 cells/mm3) 
hilar/mediastinal lymphadenopathy and lower lobe infiltrates are 
common 41. As chest radiographs may appear normal in 7-14% of 
cases, a high index of suspicion must be maintained in evaluating an 
HIV-infected patient with symptoms suggestive of TB. The finding of 
low density lymph nodes with peripheral enhancement on a contrast-
enhanced chest computed tomography (CT) scan is highly predictive of 
tuberculosis. Cavitation is unusual at advanced stage of 
immunosuppression, and infiltrates more often are diffuse or 
interstitial. 
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DIAGNOSIS  
  In children the majority of tuberculosis cases are diagnosed 
clinically without microbiological confirmation. The diagnosis is based 
mainly on clinical suspicion and radiological manifestation. In children 
with TB and HIV, special consideration is required in assessing results 
of tuberculin skin test and Acid-fast bacillus smear and culture. 
 
TUBERCULIN SKIN TEST 
HIV infection causes depression of cell mediated immunity, 
which can reduce the sensitivity and reliability of the tuberculin skin 
test. The TST is often negative, especially in those with more advanced 
HIV disease. Only one-third to less than half of children co-infected 
with TB and HIV have a positive tuberculin test (42,44,45) . Because of 
the higher risk of tuberculosis in children living in households with 
HIV-infected adults and because of diminished immune responses in 
children with HIV infection, the American Academy of Pediatrics 
recommends using induration ≥5mm as the criterion for diagnosis of 
tuberculous infection46. These criteria have not been adequately 
evaluated in developing countries, especially in those where BCG 
vaccination is a part of routine childhood immunization. 
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Although a positive result increases the likelihood of TB, a 
negative result does not exclude the diagnosis. Therefore diagnosis 
evaluation for TB should be undertaken in all children with clinical 
feature compatible with TB, regardless of the results of TB. 
 
There are recent reports of restoration of delayed 
hypersensitivity on skin testing, including tuberculin skin testing in 
HIV-infected patients who begin highly active antiretroviral therapy. 
This reaction reflects restoration of the anti M-tuberculosis cell 
mediated immune response, a phenomenon that usually occurs within 
the first month of therapy. 
 
Polymerase chain reaction and gene probes are approved for 
rapid identification of M.tuberculosis in sputum smears that are 
positive for acid-fast bacilli. These rapid tests are more sensitive than 
traditional staining methods but are not as sensitive as culture. Smears 
from extrapulmonary sites (e.g., bone marrow, lymph nodes) are often 
negative for acid-fast bacilli. 
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BACTERIOLOGICAL EXAMINATION 
All patients suspected of having pulmonary tuberculosis should 
have 3 sputum specimens obtained on 3 consecutive days, and these 
specimens should be examined for AFB and cultured for mycobacteria. 
Contrary to what one would expect, smears and cultures are more often 
negative in HIV-infected adult patients with tuberculosis47. Similar 
findings are reported among children with co-infection(42,44). 
 
In general the rate of smear positivity correlates with the extent 
of radiographic disease. For example, patients with cavitary lesions due 
to active tuberculosis will almost always have positive smears, whereas 
a negative smear in a patient with minimal disease on chest radiograph 
would not be unusual, and would not rule out active TB. However, in 
HIV infected patients positive smears may be seen with relatively little 
radiograph involvement. Despite this, it is recommended that 
aggressive attempts be made to obtain a positive culture to differentiate 
between M.tuberculosis and other mycobacteria, as well as to 
determine the antimicrobial susceptibility. 
 
Smears from needle aspiration and Ziehl-Neelson staining are 
often negative in HIV patients who have tuberculous lymphadenitis48. 
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Hence biopsy with histopathological examination and culture of lymph 
node tissue are recommended to establish the diagnosis. 
 
Diagnostic tests for TB can be broadly divided into 
1. Demonstration/isolation of Mycobacterium tuberculosis 
2. Demonstration of host response to exposure to M.tuberculosis 
 
(A) DEMONSTRATION OF M.TUBERCULOSIS OR ITS 
COMPONENTS  
1. Ziehl-Neelson Staining  
2. Special stains (Flurochrome stain, Auramine-O-stain etc.,) 
3. Culture of mycobacterium tuberculosis 
- LJ medium 
- BACTEC radiometric assay 
4.  Polymerase chain reaction 
 
(B) DEMONSTRATION OF HOST RESPONSE TO 
EXPOSURE TO M.TUBERCULOSIS 
1. Serodiagnosis  
2. Tuberculin skin testing 
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Newer diagnostic modalities including molecular methods of 
diagnosis of tuberculosis may yield better results than routine smear 
and culture in HIV infected population, but these methods need further 
evaluation. Moreover, these methods for diagnosis are seldom 
available in regions where the two infections most frequently co-exist. 
 
DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION 
Screening for latent tuberculous infection is an essential step in 
controlling the spread of tuberculosis. Screening for LTBI is 
recommended in persons at risk for recent infection and in those with 
increased risk of progression to active disease once infected, including 
HIV-infected persons. 
 
The TST is currently the only method available for identifying 
LTBI. Routine annual TST is recommended in HIV infected 
individuals. A reaction of ≥5mm induration is considered positive for 
HIV infected patients and those with other forms of severe 
immunosuppression, person who are close contacts of infectious cases, 
and persons with abnormal radiographs consistent with tuberculosis. 
Use of 5mm cutoff is supported by a prospective study in the United 
States demonstrating that the risk of tuberculosis was significantly 
 37
higher in HIV-infected persons with TST≥5mm of induration than in 
those who have a reaction of <5mm 46.  
 
Testing with tuberculin purified protein derivative is dependant 
on the presence of an intact cell mediated immune response. In the 
setting of HIV infection, reduced CMI can lead to decreased delayed-
type hypersensitivity responsiveness, resulting in false-negative skin 
test. The prevalence of positive TST≥5mm was shown to decrease with 
decreasing CD4 T cell counts. 
 
Application of multiple skin antigens (e.g. candida, mumps, 
tetanus toxoid etc.,) referred to as anergy testing, has been used to 
access cell-mediated immune function and to distinguish true negative 
from false negative tuberculin skin test results. In 1991, the CDC 
recommended that anergy testing be performed in conjunction with 
TST in HIV-infected persons based on the premise that anergic HIV-
infected individual at high risk for tuberculosis infection would benefit 
from treatment with INH. In 1997, the CDC revised its 
recommendations and no longer recommends anergy testing while 
screening for M.tuberculosis infection in HIV-infected persons. The 
revised recommendation is based on the following points. First, there 
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are no standardized guideline for performing anergy skin testing. The 
appropriate number of control antigens to administer or the appropriate 
cut off for interpreting a test as positive in nor known. Second, the 
response to skin testing with control antigens as well with tuberculin 
can vary over time. Several studies have demonstrated that HIV-1 
seropositive individuals can regain DTH responsiveness with time 49. 
The only factor associated with regaining DTH responsiveness was the 
CD4-T cell count, the higher the CD4 count, the more likely the 
individual regains DTH responsiveness. 
 
In some with tuberculous infection, DTH responsiveness may 
decrease with time. A second TST, applied weeks to month after the 
first, can boost the DTH response resulting in a positive skin test 
reaction. Such responses are considered true evidence of tuberculous 
infection. 
 
NATURAL HISTORY 
Although the immune response to M. tuberculosis is important 
in controlling disease, immune activation may also be associated with 
increased HIV viral load and accelerated progression of HIV infection. 
HIV-infected patients with tuberculosis do not survive as long as HIV 
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infected controls without tuberculosis, even after controlling for 
baseline CD4 T-cell count. When tuberculin positive HIV infected 
patients were given INH therapy, they were less likely to develop 
AIDS and less likely to die. Thus, it is likely that tuberculosis acts to 
accelerate the clinical course of HIV infection. 
 
Although increased viral replication is thought to play a role, the 
mechanisms by which tuberculosis accelerates progression of HIV 
disease are not known with certainty. High levels of TNF-α which are 
known to increase HIV replication in T-cell clones, have been 
demonstrated in both HIV-1 seropositive and seronegative tuberculosis 
cases. 
 
Moreover, investigators have shown that M. tuberculosis or 
purified protein derivative can also increase viral replication in infected 
T lymphocytes and monocytes 36.  
 
TREATMENT 
Standard treatment regimens: 
Anti-TB therapy is equally effective in HIV negative and HIV 
positive patients. The weight of the evidence to date indicates that the 
rate of TB relapse after short-course (6-month rifampicin based) 
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therapy is similar for HIV-positive and HIV negative patients, although 
this remains somewhat controversial. In general the same treatment 
regimen may be used regardless of HIV status 49. The American 
Thoracic Society TB treatment guidelines (currently under revision) 
will likely include a recommendation to extend the duration of therapy 
to 9 months (regardless of HIV status) in persons who have both 
cavitary pulmonary disease on initial presentation and positive-sputum 
cultures after 2 months of treatment. These changes are based on 
results of a recent TB-treatment study conducted by CDC, in which 
HIV negative adults with pulmonary disease who met these criteria had 
a relapse rate of >20% far higher than clinically acceptable relapse rate 
of <5% 49. 
 
PULMONARY TUBERCULOSIS 
For drug susceptible pulmonary TB standard 6 month therapy 
with isoniazid (INH), rifampicin (RIF) Pyrazinamide (PZA) and 
Ethambutol (EMB) daily for intitial two months followed by INH and 
RIF daily or twice weekly, for atleast four additional months is 
recommended. Conversion from sputum positive to sputum negative 
with this regimen is similar in HIV seropositive and seronegative 
patients with tuberculosis. However it is not known if relapse rates are 
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higher in HIV infected patients. Hence some experts recommend 
extending the treatment to 9 months in those who show slow response. 
Slow response is defined as sputum positivity or persistence of signs 
and symptoms of disease after 2 months of therapy. DOTS is 
recommended wherever possible 49. 
 
EXTRAPULMONARY TUBERCULOSIS 
The drug regimen and duration of treatment used for pulmonary 
tuberculosis are generally adequate to treat most forms of 
extrapulmonary tuberculosis. However, for certain forms of 
tuberculosis such as meningitis and bone and joint tuberculosis, a 9 
month regimen of rifamycin containing regimen is recommended49. 
 
DRUG RESISTANT TUBERCULOSIS 
The risk of drug resistant tuberculosis is higher among those co-
infected with HIV50. The reasons for this is not clear, but this might 
reflect the fact that a higher proportion of tuberculosis disease in HIV 
infected individuals follows recently acquired infection. 
 
In recent years there had been an increasing number of reports of 
rifampicin monoresistance in HIV co-infected patients. The reasons for 
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this is not fully understood. Possible reasons include (1) increased rates 
of bacterial replication in an environment of suppressed CMI. (2) 
selective drug malabsorption and (3) inadequate tissue penetration of 
the drug. 
 
For isoniazid-resistant tuberculosis, a regimen containing 
Rifamycin, Pyrazinamide and Ethambutol may be used for the full 
duration of treatment 6-9 months. Intermittent therapy may be used 
after daily therapy for the initial 8 weeks. 
 
For tuberculosis resistant only to rifampicin a 9 month regime 
consisting of INH, EMB, PZA and streptomycin for the initial two 
months, followed by INH, PZA and streptomycin, for the next 7 
months is recommended. 
 
In multidrug resistant tuberculosis resistant to INH and RIF, 
aggressive treatment with a regime that contains an aminoglycoside or 
capreomycin and a fluroquinolone is recommended. The duration of 
therapy must be at least 24 months after culture conversion. 
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PHARMACOKINETIC INTERACTION  
A central aspect of TB treatment in HIV infected patients is the 
pharmacokinetic interactions between rifamycins and PI and 
NNRTI’S. Although these interactions do not preclude the concomitant 
use of potent antireteroviral therapy and anti TB therapy clinicians 
must be aware of these interactions and adjust dosages accordingly. 
Although large studies of the effectiveness of rifabutin based regimens 
in co-infected patients concomitantly receiving antireteroviral therapy 
are underway, the results will not be available for 1 to 2 years. 
 
Rifampicin induces the enzyme CPY450 that increases the 
metabolism of protease inhibitors resulting in lower serum levels of 
these drugs 49. Since PI resistant mutants of HIV may emerge if 
optimal levels of the drug are not maintained during therapy 
concomitant therapy with rifampicin and PI’s is not recommended. 
 
On the other hand the protease inhibitor ritonavir inhibits 
CPY450, which results in increased concentration of rifabutin and 
resultant toxicity. Since current evidence indicates that the anti-
tuberculosis activity of rifabutin is equal to that of rifampicin, it is not 
recommended that this drug be used instead of rifampicin in the 
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treatment of TB in patients receiving PI’s, the PI ritonavir should not 
however, be used in treatment regimens containing rifabutin. 
 
DIRECTLY OBSERVED THERAPY 
DOT is becoming the standard of care of TB (51, 52). A large body 
of evidence has conclusively proven that a large proportion of patients 
do not take medications regularly as prescribed and that it is not 
possible to predict which patients will not adhere to treatment. Surprise 
home visits as per studies from Tuberculosis Research Centre, Chennai 
showed a much greater degree of non-adherence than pill counts or 
urine tests 53. 
 
The efficacy of short-course intermittent treatment has been 
conclusively demonstrated in controlled clinical trials in India and 
elsewhere 54. Short course treatment has been documented to be 
effective for extrapulmonary TB. Since the doubling time of 
M.tuberculosis is 18-24 hours, compared with 12-20 minutes for most 
bacteria intermittent therapy given twice or thrice weekly is as 
effective as daily therapy 55. Among HIV infected children, directly 
observed therapy has been associated with improved survival. Because 
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of these benefits, DOT therapy is recommended by the American 
Thoracic Society, the CDC and WHO 51. 
 
WHO recommended Treatment regimen 
Category of 
treatment 
Type of patients 
Regimen 
Initial phase 
Continuation 
phase 
Category I 
New sputum smear positive 
PTB, New sputum negative 
PTB with extensive 
parenchymal involvement. 
New cases of severe forms of 
extrapulmonary TB 
2H3R3Z3E3 4H3R3 
Category II 
Sputum smear-positive relapse, 
Treatment failure Treatment 
after default  
2H3R3Z3E3S3
/ 
1H3R3Z3E3 
5H3R3E3 
Category 
III 
New smear negative and 
extrapulmonary, not seriously 
ill 
2H3R3Z3 4H3R3 
 
Sputum examined after 2 months for patients for Category I and 
after 3 months for patients in Category II 26. All treatment thrice 
weekly. Category I and Category II extended one month if smear 
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positive at end of initial intensive phase. H-Isoniazid, R-Rifampicin, Z-
Pyrazinamide, E-Ethambutol, S-Streptomycin. 
 
HIV AND PARADOXICAL REACTION TO TREATMENT 
Patients who receive anti-tuberculosis treatment along with anti-
retroviral therapy may manifest a paradoxical worsening of symptoms, 
which are attributable to a recovery of tuberculin hypersensitivity as a 
result of therapy56. Such patients manifest with hectic fever, 
lymphadenopathy, worsening of chest radiographic findings (miliary 
infiltrates and pleural effusion) and worsening of original tuberculosis 
lesions. Paradoxical worsening is thought to represent an improvement 
of the host’s immune response to mycobacterial antigens during the 
course of treatment leading to more intense inflammation at sites of TB 
disease. 
 
The course of paradoxical worsening can be brief or prolonged 
with multiple exacerbations and recurrences. Discontinuation or 
changes in tuberculosis or antiretroviral therapy is rarely required in 
most situations. A short course of steroids to suppress the immune 
response may ameliorate some of the signs and symptoms, such as 
lymphadenopathy. 
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TREATMENT OF LATENT TB INFECTION 
The risk of progressing to active TB is high among HIV 
seropositive persons infected with M.tuberculosis. Therefore all HIV-
infected children with evidence of latent M.tuberculosis should receive 
treatment as the WHO recommends treating latent TB infection. 
Despite strong evidence supporting the rationale of INH preventive 
therapy in latent TB infection, implementation of IPT has not been 
widespread in countries with high TB burden. This is due to recurring 
concerns over drug resistance, short course of IPT efficacy and 
difficulties in ruling out active TB in populations with high HIV 
prevalence with limited diagnostic tools available. 
 
 48
WHO recommendations for the treatment of HIV and TB co-
infection with reference to CD4 cell count 
 
CD4 cell count Recommended regimen Comments 
<200 mm³ Start TB treatment. Start ART as 
soon as TB treatment is tolerated 
(2 weeks to 2 months). EFV 
containing regimens 
Recommended 
ART  
200 to 350 mm³ Start TB treatment. Start one of 
the below regimens after 
initiation phase. EFV containing 
regimens or NVP regimens in 
case of rifampicin free 
continuation phase TB treatment 
regimen  
Consider ART 
>350 mm³ Start TB treatment Defer ART 
CD4 count not 
available  
Start TB treatment  Consider ART 
  
BCG VACCINATION  
There are a few case reports of disseminated BCG infection in 
individuals with HIV. However several studies in developing countries 
have documented that adverse reactions following BCG vaccination in 
HIV infants are no higher than in non-infected infants 57. Therefore 
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BCG vaccination is recommended for infants of HIV infected mothers 
in countries where it is a part of routine immunization schedule, 
provided the children do not have evidence of advanced 
immunodeficiency. However the efficacy of BCG in HIV infected 
children is not known. One small case control study showed no 
efficacy in HIV infected children compared to 59% efficacy in 
uninfected children of HIV seropositive mothers 58. 
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BACKGROUND OF THE STUDY 
 
Tuberculosis is a life threatening, transmissible and pandemic 
disease, especially among HIV infected patients. In developing 
countries like India, where HIV infection is becoming prevalent and 
where TB infection has long been endemic, the incidence is increasing. 
 
HIV infected children are at increased risk of developing 
tuberculosis due to depressed cell mediated immunity.  
 
This study is aimed to identify the prevalence and the clinical 
profile of TB in HIV seropositive children in our region, which will 
help in early diagnosis and management. 
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MATERIALS AND METHODS 
 
Nature of the study: Descriptive study 
 
Study population : 100 children screened positive for HIV at VCTC 
in ART centre, and diagnosed to have TB infection as per RNTCP 
guidelines at GMKMCH Salem. 
 
Period and place of study: This study was conducted over a period of 
12 months from May 2008- April 2009 at GMKMCH Salem. 
 
Inclusion criteria:  
¾ Children who are seropositive in the age group of 18 months to 
12 years registered in the ART centre. 
¾ Children with stigmata for TB like fever, cough with 
expectoration lasting for more than three weeks, loss of appetite 
and loss of weight.  
¾ Children who are suffering from Extra pulmonary TB infection 
like TB pericarditis, TB Meningitis, TB Abdomen, Isolated TB 
Potts spine, Disseminated TB. 
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EXCLUSION CRITERIA: 
Children < 18 months were not taken into consideration, as the 
facility for making diagnosis of HIV by PCR was not available in our 
centre. 
 
PROFORMA 
A special proforma was designed to record the following 
information. 
¾ Demo graphic data 
¾ History at presentation 
¾ Clinical findings  
¾ Nutritional status 
¾ Developmental history 
¾ Parental and sibling status 
¾ Mode of transmission 
¾ Socio economic history 
¾ Stage of the disease 
¾ Immunisation history 
Informed consent was obtained from the parent/ guardian for 
registering the required data. The seropositive children were subjected 
to the following further investigation that include, 
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¾ Blood hemoglobin 
¾ Total count  
¾ Differential count 
¾ Erythrocyte sedimentation ratio 
¾ Liver function test 
¾ Sputum for AFB/ Resting gastic juice analysis 
¾ Mantoux test 
¾ Chest x-ray PA view/ AP view 
¾ CD4 count / CD4 % 
¾ FNAC 
¾ USG Abdomen 
¾ C T scan brain 
¾ CSF 
¾ Others (x-ray spine) etc. 
 
STUDY LIMITATIONS 
The confirmation of HIV infection could not be done by 
Western Blot analysis. The sputum positivity for tuberculosis infection 
in HIV infected children is low. Hence for confirmation of 
Tuberculosis infection in these seropositive individuals, sputum culture 
must be done which could not be done in our study. 
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OBSERVATION & RESULTS 
 
The study population was derived from the persons attending 
outpatient department at GMKMCH, Salem. Out of 512 confirmed 
cases of HIV infection, 100 were found to be suffering from 
Tuberculosis, they formed the study population. 
 
The prevalence of tuberculosis in HIV infected children was 
19.53%. 
 
 
512
100
Total No. of HIV
Infected Children
No. of patients with HIV
& TB
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SEXWISE DISTRIBUTION 
 
Out of the 100 children with HIV and TB infection 62 were 
males and 38 were females. The ratio was 1.63:1. 
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AGEWISE DISTRIBUTION 
 
The age-wise distribution of cases were as follows 
Age group Male Female 
1 ½ to 5 Years 19 11 
6-12 Years 43 27 
Total 62 38 
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MODE OF TRANSMISSION 
Mother to child transmission accounted for the highest route of 
transmission (97%). 
In two children the actual mode of transmission could not be 
identified (2%) 
One child was most likely affected due to Blood transfusion 
given during acute illness (1%) 
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PLACE AND MODE OF DELIVERY 
92 Children were delivered by normal vaginal delivery out of 
which 13 were delivered at home, rest 79 were delivered in hospital. 8 
Children were delivered by emergency LSCS. 
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NEVIRAPINE/HAART THERAPY DURING ANTENATAL 
PERIOD 
Out of 100 children only 2 children received Nevirapine during 
the Peripartum period. None of the mothers received HAART during 
Antenatal period. 
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FEEDING 
82 Children received breast milk for the initial 4 months. 9 
children received cow’s milk and 8 children received both cow’s milk 
and breast milk. Only one child was completely replaced with milk 
substitute. 
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DEVELOPMENTAL HISTORY 
98 Children presented with normal developmental history only 2 
children had delayed motor milestones. 
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NUTRITIONAL STATUS 
 The nutritional status of the children was classified as per IAP 
classification of malnutrition as follows. 
Nutritional Status* Weight for age (% of expected) No. of Children 
Normal > 80 15 
Grade I PEM 71-80 17 
Grade II PEM 61-70 27 
Grade III PEM 51-60 26 
Grade IV PEM < 50 15 
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SYMPTOMS 
The common symptoms present in the study group was as follows: 
Fever    - 89% 
Cough   - 66% 
Loss of appetite  - 52% 
Lymphadenopathy  - 13% 
Diarrhea   - 6% 
Abdominal pain  - 5% 
ALOC/Seizure  - 5% 
Back pain   - 1% 
 
89
66
52
13
6 5 5 1
0
10
20
30
40
50
60
70
80
90
100
Fe
ve
r 
Co
ug
h
Lo
ss
 of
 ap
pe
tite
Ly
mp
ha
de
no
pa
thy
Dia
rrh
ea
Ab
do
mi
na
l p
ain
AL
OC
/Se
izu
re
Ba
ck
 pa
in
Symptoms
N
o.
 o
f C
hi
ld
re
n
 
 62
 
SYSTEM EXAMINATION 
The clinical presentations was Lymphadenopathy mostly 
cervical (11%) and axillary in 1%. In respiratory system signs of 
pneumonia was present in 60%, 2 children had pleural effusion, 2 had 
bronchiectasis, 2 children had consolidation/collapse. Thus respiratory 
system was involved in 66% of children. 
Gastrointestinal system (9%) 5 children presented with 
hepatomegaly, 5 children presented with hepatosplenomegaly and 4 
children had ascites.  
Oral lesion (24%) 14 children had Oral candidiasis, 4 children 
had Apthous ulcers, 3 children had Angular stomatitis and 3 children 
had Herpes simplex. 
Skin Lesions (15%) 6 children had Herpes zoster, 4 children had 
Molluscum contagiosum, 2 children had scabies, 2 had extensive 
impetigo and 1 child had rash. 
Central Nervous System (7%) Meningitis are present in 7 
children out of which 1 child had Cranial nerve involvement. 
Spinal involvement was present in 1 child (Pott’s spine). 
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SYSTEM INVOLVEMENT PRESENTATION 
Respiratory System (66%) 
 
Pneumonia – 60% 
Pleural Effusion – 2% 
Bronchiectasis – 2% 
Consolidation/Collapse -2% 
Gastrointestinal system (9%)  
 
 
Hepatomegaly – 5% 
Hepatosplenomegaly – 5% 
Ascites – 4% 
 
Lymphadenopathy (12%)  
 
Cervical – 11% 
Axillary – 1% 
 
Oral lesion (24%) 
 
Oral candidiasis – 14% 
Apthous ulcers – 4% 
Angular stomatitis – 3% 
Herpes simplex – 3% 
 
Skin Lesions (15%) 
 
Herpes zoster-6% 
Molluscum contagiosum-4% 
Scabies-2% 
Extensive impetigo-2% 
Rash-1% 
 
Central Nervous System (7%) 
 
Meningitis -7% 
Cranial nerve involvement -1% 
 
Spinal involvement (1%) Pott’s spine – 1% 
 
 
 64
EXTRAPULMONARY MANIFESTATIONS: 
26 Children had extrapulmonary system involvement: 
Lymphadenopathy  - 13 
TB Meningitis  - 6 
TB abdomen  - 4  
Disseminated TB  - 2 
 TB Spine   - 1 
  
SPUTUM POSITIVITY 
Sputum for AFB Number 
Sputum Positive 9 
Sputum Negative 91 
 
CORRELATION BETWEEN SPUTUM POSITIVITY AND 
CD4 COUNT 
CD4 count Sputum Positive Sputum Negative 
0-100 1 13 
101-200 - 7 
201-300 1 11 
>300 7 60 
Total 9 91 
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MANTOUX TEST 
Mantoux testing was done in 25 children who were admitted in 
our hospital, out of which only one child was mantoux positive. 
 
Mantoux reading Number 
0-4 mm 2 
5-9 mm - 
10-14 mm 1 
 
 
CD4 CELL COUNT 
The CD4 cell count was as follows: 
 
CD4 cell count/mm3 Number 
0-100 14 
101-200 7 
201-300 12 
>300 67 
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WHO CLINICAL STAGING 
 
WHO STAGE NUMBER 
Stage III 87 
Stage IV 13 
TOTAL 100 
 
 
The CD4 count correlation with WHO clinical staging was as 
follows: 
 
CD4 COUNT 
WHO STAGE 
STAGE III STAGE IV 
0-100 9 5 
101-200 6 2 
201-300 12 2 
>300 59 5 
 Total 86 14 
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CHEST X-RAY FINDINGS 
 
CHEST X-RAY FINDINGS NUMBER 
Lobar/segmental infiltrates 41 
Diffuse infiltrates 25 
Miliary mottling 5 
Pleural effusion 4 
Hilar adenopathy 4 
Bronchiectasis 3 
Normal 18 
Total 100 
 
 
41
25
5 4 4 3
18
0
5
10
15
20
25
30
35
40
45
Lo
ba
r/s
eg
m
en
ta
l
in
fil
tra
te
s
D
iff
us
e 
in
fil
tra
te
s
M
ili
ar
y 
m
ot
tli
ng
P
le
ur
al
 e
ffu
si
on
H
ila
r
ad
en
op
at
hy
B
ro
nc
hi
ec
ta
si
s
N
or
m
al
Chest X-Ray Findings
N
o.
 o
f C
hi
ld
re
n
 
 68
 
The correlation of CXR findings with CD4 count: 
CD4 
Count 
Segmental 
/Lobar 
infiltrates 
Diffuse 
infiltrates
Miliary 
TB 
Pleural 
effusion
Bronch-
iectasis 
Hilar 
adenopathy Normal
0-100 3 5 2 - 1 - 2 
101-
200 - 1 1 - - - 2 
201-
300 7 3 - 2 - 1 1 
>300 31 16 2 2 2 3 13 
Total 41 25 5 4 3 4 18 
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DISCUSSION 
 
Among the 512 patients infected with HIV infection, 100 
children were having TB co-infection, with a prevalence of 19.53%. 
This corresponds to other studies like Merchant et al 59 where 29.5% 
were co-infected. Lodha et al 60 (59.1%) and Dhurat et al 61 (67.5%) 
have also recorded the increased prevalence of HIV-TB co-infection. 
Out of 100 seropositive children with TB co-infection, 62% 
were males and 38% were females. This indicates that the male:female 
ratio is 1.6:1. The prevalence of HIB-TB co-infection is 70% in the age 
group of 6-12 years. This correlates well with the observations of 
Shahab, Afzal et al 62 where the male:female ratio was 2.3:1 and 
prevalence of coinfection was 72.4% in the age group of 1-9 years. 
History of contact with TB was present in 38% as against 47% 
in the results of Shahab, Afzal et al 62 . 73% of the children in our 
study population were taken care by their parents (father 55% and 
mother 18%) rest 27% were orphaned and taken care by their grand 
parents. 
97 Children acquired infection by perinatal transmission, one 
child has infected following blood transfusion. In two children the 
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actual mode of transmission could not be identified. Verghese VP, 
Cherian et al63 study reported that perinatal transmission was the 
predominant root of transmission (87%) followed by blood transfusion 
(10%) and the mode of transmission could not be ascertained in rest 
3%. Blood and blood products remain an important source of infection 
in 10-30% of total cases in developing countries60.  
 The children in stage IV were severely malnourished and 
belonged to Grade III & Grade IV PEM. All children in our study 
population were on regular Cotrimoxazole prophylaxis. 
Analysis of the clinical manifestations of TB in seropositive 
children 
Fever was the most common clinical manifestation followed by 
cough and loss of appetite. 
Symptom Our study Shahab, Afzal et al 62 
Fever 89% 87.6% 
Cough 66% 41.2% 
Loss of appetite 52% 48.5% 
Lymphadenopathy 13% 23% 
Abdominal pain 5% 1% 
Diarrhea 6% 1% 
Neurological (ALOC/seizures) 5% 9% 
Others (Back pain) 1% - 
  
 71
Systemic examination revealed respiratory system findings and 
Lymphadenopathy were present in 66% and 12% respectively. About 
9% had hepatomegaly/hepatosplenomegaly with ascites in 4% of the 
children. 24% of children presented with oral lesions(mostly oral 
candidiasis 14%) and skin lesions was present in 15%. 
General/system examination Our study Shahab, Afzal et al 62 
Respiratory system findings 66% 36.5% 
Lymphadenopathy 13% 28% 
Hepatomegaly 5% - 
Hepatosplenomegaly 4% 11.5% 
Skin lesions 15% 3% 
Oral candidiasis 14% 30% 
CNS involvement 7% 5% 
  
Extrapulmonary TB was seen in 26% of children in our study 
which includes Lymphadenopathy 13%, TB Meningitis 6%, TB 
abdomen 4%, Disseminated TB 2% and TB spine 1%. This finding 
corresponds to the earlier observations of Dhurat et al61 and 
Merchant et al59. 
The sputum positivity in our study shows that only 9% of the 
children are sputum positive. Sputum culture for M.Tuberculosis 
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remains the gold standard for the diagnosis of Pulmonary TB. In 
resource poor countries the diagnosis is heavily dependent on the 
sputum AFB smear. HIV infected children have reported to have a 
lower yield on AFB smears as observed in Mukadi et al42, Garay JE 
et al44. Verghese VP et al63, reported only 4% smear positive cases in 
HIV children. 
In our study Mantoux was done in 25 children who were 
admitted in our hospital and only one child was Mantoux positive with 
more than 10 mm induration. This correlates well with study by 
Mukadi et al42 which shows an increased incidence of anergy in HIV 
infected and AIDS patients. 
In our study CD4 cell count less than 300 was observed in 33 
children. In these children the predominant X-ray lesions were Hilar 
adenopathy, lower lobe infiltrations, diffuse infiltrates and miliary 
mottling. Upper lobe infiltrates was common with higher CD4 count 
mean 350. These finding correlates well with Verghese VP et al63 and 
Shahab, Afzal et al 62. 
The most important finding of this study is the impact of HIV 
related immunosuppression among children with TB. 8 children with 
CD4 % of less than 10% died during 6 months of therapy. This finding 
correlates well with the study of Mukadi et al42 
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CONCLUSION 
 
¾ Tuberculosis is a common opportunistic infection among HIV 
seropositive individuals. 
¾ Males are commonly affected than females. 
¾ Tuberculosis occurs early in HIV infection even before CD4 count 
falls to very low levels. 
¾ Fever, cough, loss of appetite and loss of weight are the most 
common symptoms observed in HIV-TB co-infection. 
¾ Extrapulmonary TB is present in 30% of HIV seropositive children. 
¾ Sputum negativity was more commonly seen in TB of HIV 
seropositive individuals. 
¾ Mantoux anergy was observed with lower CD4 counts. 
¾ This study documents the importance of HIV infection as an 
independent risk factor for the development of TB in children and 
also demonstrate that HIV related immunosuppression as critical 
risk factor for mortality in this population. 
¾ With the conventional sputum positivity and Tuberculin test not 
providing an adequate diagnostic help, familiarity with clinico 
radiological spectrum of TB and HIV co-infection will help in early 
diagnosis and improve survival among HIV seropositive children.  
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1 12 M 17 MTC - I/LN BF - ↓ 1,2 IV - - UZ  577 (17%) - - - III P I C 9
2 9 F 16 MTC - I/CS BF - ↓ 1,6 VII - - LZ 89 (10%) - - CS IV EP I C 9
3 7 M 17 MTC - I/LN BF + ↓ 1,2,3 IV - - LZ 374 (14%) - - - III P I C 9
4 4 1/2 F 14.5 MTC - I/LN BF - ↓ 1,2 IV - - UZ 693 (19%) - - - III P I T 9
5 10 M 11 MTC - I/LN BF + ↓ 4 I - - LZ 283 (9%) + - - III EP II DE 9
6 12 M 25 MTC - I/LN BF + ↓ 1,3,6 VI - - LZ 28 (5%) - - CSF+ IV EP I D 9
7 7 F 17 MTC - I/LN BF - ↓ 1,2 IV - - LZ 777 (11%) - - - III P I C 9
8 6 M 15 MTC - I/LN BF + ↓ 1,2,3 IV - - M 98 (4%) - - - III P I C 9
9 4 F 14.5 MTC NVP I/LN CM - ↓ 2,3, 5,6 IV, V - + PE
1070 
(16%) -
HSM, 
PE, A - III EP I C 9
10 11 F 20 MTC - I/LN BF - ↓ 1,2,5 V - - B 671 (11%) -
HEP, 
A, N - IV EP I C 9
11 9 M 18 MTC - I/LN Mix - ↓ 1,2,6 IV, V - - DI 81 (4%) -
HEP,
A
CT 
Chest, 
B
IV EP I C 9
12 3 1/2 M 10 MTC - I/LN Mix + ↓ 1,2 IV - - DI 889 (13%) - HEP - III P I C 9
13 5 F 11 MTC - I/LN BF - ↓ 1,2 IV, V - - B 282 (10%) - HSM - III P I C 9
MASTER CHART
14 11 1/2 M 13 MTC - I/LN BF - ↓ 1,2,6 II, V - - LZ 680 (15%) - -
CT 
Norm III P I C 9
15 11 M 19.6 MTC - H/LN BF - ↓ 1,2 V - - DI 82 (8%) - - - III P I C 9
16 12 M 20 MTC - I/LN BF - ↓ 1,2,3 IV - - LZ 356 (26%) - - - III P I C 9
17 9 M 17 MTC - I/LN BF - ↓ 1,2,3 IV - - LZ 188 (16%) - - - III P I C 9
18 8 M 18.6 MTC - I/LN Mix - ↓ 4 I, IV - - UZ 604 (15%) + - - III P I, II T 9
19 11 M 20 MTC - H/LN BF - ↓ 1,2,5 II, IV - - LZ 252 (12%) - Norm - III P I C 9
20 9 M 18 MTC - I/LN BF - ↓ 1,2,3 IV - - LZ, MZ
1024 
(12%) - - - III P I C 9
21 10 M 18 MTC - I/LN BF - ↓ 1,2,3 IV - - LZ 89 (3%) - - - III P I C 9
22 4 M 10 MTC - I/LN BF + ↓ 1,2,3 IV - - LZ 206 (11%) - - - III P I D 9
23 4 F 15 MTC - I/LN BF - ↓ 1,2 IV - - LZ 773 (15%) - - - III P I C 9
24 9 F 18 MTC - I/LN BF - ↓ 1,2,3 IV - - LZ 656 (11%) - - - III P I C 9
25 11 F 20 MTC - I/LN BF + ↓ 1,2,3 IV - - M 805 (25%) - - - III P, EP II C 9
26 12 F 29 MTC - I/LN BF + ↓ 1,2,3 IV - - LZ 269 (12%) - - - III P I T 9
27 6 M 12 MTC - I/LN BF + ↓ 1,2, 3,4 I, II - - -
294 
(13%) + - - III EP I C 9
28 11 M 24 MTC - I/LN BF - ↓ 1,3 II, V - - - 16 (3%) - HEP CT + IV EP I D 9
29 9 M 18 MTC - H/LN BF + ↓ 1,2, 3,4 I, II - - -
1019 
(37%) + - - III EP I C 9
30 3 F 10 MTC - I/LN BF - ↓ 1,2,3 II, IV + - LZ 853 (17%) - HSM - III P I C 9
31 2 M 11 MTC NVP I/LN Mix - ↓ 4 I - - - 858 (15%) + - - III EP I C 9
32 6 M 12 MTC - I/LN CM + ↓ 1,4 I - - - 618 (20%) + - - III EP I C 9
33 3 M 9 MTC - I/LN BF - ↓ 1,3,5 IV, VI - - M 582 (16%) - -
CT +, 
CSF + IV P, EP I, II C 9
34 7 M 10 MTC - I/LN BF + ↓ 1,6 VI - - - 1278 (28%) - - CSF+ IV EP I T 9
35 5 M 15 UK - H/LN BF - ↓ 1,4 I, III - - - 1312 (30%) + - - III EP I C 9
36 12 F 22 BT - I/LN BF - ↓ 1,2,3 IV - - HA 287 (7%) - - - III P I C 9
37 5 MF 15 MTC - I/LN BF - ↓ 1,3,5 III, IV - - DI 18 (4%) -
HEP, 
N - III EP I D 9
38 6 M 9.7 MTC - I/LN Mix + ↓ 1,2,3 IV - - DI 71 (12%) - - - III P I D 9
39 11 M 17 MTC - I/LN BF - ↓ 1,2,3 II, III - - PE 777 (23%) - - - III P I IR 9
40 7 M 14.2 MTC - I/LN BF + ↓ 4 I, III - - - 671 (10%) + - - III EP I C 9
41 9 F 16 MTC - I/LCS Mix + ↓ 1,2, 3,4 IV + -
LZ, 
MZ
1017 
(21%) - - - III P I C 9
42 10 F 25 MTC - I/LN BF - ↓ 1,2,3 III + - LZ 556 (23%) - - - III P I C 9
43 4 M 11 MTC - I/LN BF - ↓ 1,2,3 III + - HA 612 (15%) - - - III P I C 9
44 5 M 15 MTC - I/LN BF - ↓ 1,2,3 III - - - 227 (6%) - - CT+ IV P I C 9
45 8 M 16 MTC - I/LN CM - ↓ 1,2,3 IV - - DI 410 (11%) - - - III P I C 9
46 7 M 16 MTC - I/LN BF - ↓ 1,2, 3,6 IV - - M
151 
(6%) - - - III P I C 9
47 12 M 40 MTC NVP I/LCS Mix +  ↑ 1,2,3 III, IV + + DI 1051 (32%) - - - III P I C 9
48 8 F 10 MTC - H/LN BF + ↓ 1,2,3 II, III - + LZ 260 (8%) - - - IV P I C 9
49 5 M 11.2 MTC - I/LN CM - ↓ 1,2,3 IV + - LZ 505 (8%) - - - III P I C 9
50 4 M 11.5 MTC - H/LN BF + ↓ 1,2,3 IV - - UZ 575 (25%) - - - III P I C 9
51 10 F 19.5 MTC - H/LN BF - ↓ 1,2,3 IV - - LZ 425 (23%) - - - III P I C 9
52 5 F 13 MTC - I/LN CM - ↓ 1,2,3 IV - - UZ 538 (15%) - - - III P I C 9
53 11 M 24 MTC - I/LN BF - ↓ 1,2,3 IV - - LZ 237 (16%) - - - III P I C 9
54 8 M 15 MTC - I/LN BF - ↓ 1,2,3 IV + - LZ 205 (21%) - - - III P I C 9
55 10 F 20 MTC - I/LN BF - ↓ 1,2,3 IV - - - 692 (29%) - - - III P I T 9
56 5 M 15 MTC - I/LN BF + ↓ 1,2,3 III - - DI 212 (7%) - - - III P I C 9
57 7 M 16 MTC - I/LN BF + ↓ 1,2,3 IV - - LZ 609 (18%) - - - III P I C 9
58 10 F 14.8 MTC - I/LN BF + ↓ 1,2,3 IV + - UZ 918 (25%) - - - III P I C 9
59 10 F 14 MTC - I/LN BF + ↓ 1,2,3 II, III, IV - - DI
106 
(10%) - - - III P I C 9
60 5 M 14 MTC - I/LN Mix - ↓ 1,2,3 III, IV - - UZ 893 (28%) - - - III P I C 9
61 3 M 10 MTC - I/LN BF - ↓ 1,2,3 III, IV - - PE 945 (12%) - - - III P I C 9
62 6 M 11 MTC - H/LN BF + ↓ 4 I - - - 576 (17%) +
HEP, 
A, N - III EP I C 9
63 12 F 28 MTC - I/LCS CM + ↓ 1,2,3 III, IV + - DI 416 (15%) - - - III P I IR 9
64 7 M 19 MTC - I/LN BF + ↓ 3,5 IV, V - - DI 106 (4%) - - - III EP I C 9
65 5 M 10.5 MTC - I/LCS CM + ↓ 1,2,3 III, IV - - DI 624 (18%) - - - III P I IR 9
66 12 M 19 MTC - I/LN BF - ↓ 1,2,3 II, IV - - UZ 1299 (20%) - - - III P I C 9
67 10 M 23 MTC - I/LN Mix + ↓ 1,2,3 II, IV - - DI 135 (6%) - - - III P I T 9
68 11 F 18 MTC - H/LN BF + ↓ 1,3,6 VI - - - 117 (4%) - N CSF+ IV EP I D 9
69 4 F 9 MTC - I/LN BF - ↓ 1,2,3 III, IV - - HA 1524 (32%) - - - III P I C 9
70 7 M 18 MTC - I/LCS BF - ↓ 1,2,3 IV - - MZ 378 (19%) - - - III P I C 9
71 5 M 13.6 MTC - I/LN CM - ↓ 1,2,3 III, IV - - LZ 1183 (19%) - - - III P I C 9
72 11 F 12.5 MTC - I/LN BF + ↓ 1,2,3 III, IV - - DI 512 (14%) - - - III P I C 9
73 5 M 15 MTC - I/LN BF + ↓ 1,2,3 II, III - - - 382 (16%) - - - III P I C 9
74 8 F 14 MTC - I/LN BF + ↓ 1,2,3 IV + - DI 266 (16%) - - - III P I C 9
75 3 M 10 MTC - H/LN BF + ↓ 1,2,3 IV - - DI 1163 (34%) - - - III P I C 9
76 3 F 8 MTC - I/LN BF - ↓ 1,2, 3,6 IV - - UZ
905 
(19%) - - - III P I C 9
77 10 F 21 MTC - H/LN BF + ↓ 1,2,3 IV - - DI 698 (29%) - - - III P I C 9
78 8 F 13 MTC - I/LCS BF + ↓ 1,2,3 I, III - - DI 386 (20%) - - - III P I C 9
79 6 F 16 MTC - I/LN BF - ↓ 4 IV - - - 600 (13%) + - - III EP I C 9
80 5 M 13 MTC - I/LN BF - ↓ 1,2,3 III, V - - DI 449 (17%) - - - III P I C 9
81 11 M 20 UK - I/LN BF - ↓ 2,3 IV - - - 10 (2%) -
HEP, 
N - IV EP I D 9
82 10 M 16 MTC - I/LN BF - ↓ 1,2,3 IV - - HA 81 (6%) - - - III P I T 9
83 5 F 15 MTC - I/LN BF - ↓ 1,2,3 IV - - DI 539 (12%) - - - III P I C 9
84 8 M 17 MTC - I/LN CM - ↓ 3,4 I - - - 554 (13%) + - - III EP I C 9
85 6 M 16 MTC - I/LN BF - ↓ 1,2,3 IV - - HA 495 (23%) - - - III P I C 9
86 10 M 26 MTC - I/LN BF - ↓ 1,3,4 I - - - 743 (16%) + - - III P I C 9
87 8 F 16 MTC - I/LN BF + ↓ 1,2,3 IV - - DI 574 (17%) - - - III P I C 9
88 9 F 18 MTC - I/LN BF + ↓ 1,2,3 IV - - DI 595 (29%) - - - III P I C 9
89 11 F 26 MTC - I/LN BF + ↓ 1,2, 3,4 I - - -
342 
(21%) + - - III EP I C 9
90 5 M 14 MTC - I/LN BF + ↓ 1,2 IV - - B 615 (19%) - - - III P I IR 9
91 11 M 17 MTC - I/LN BF - ↓ 1,2 IV - - DI 777 (29%) - - - III P I C 9
92 3 F 9 MTC - I/LN BF - ↓ 1,2 IV - - LZ 576 (17%) - - - III P I C 9
93 7 M 38 MTC - I/LN BF - ↓ 1 IV - - TE 791 (32%) - - - III P I C 9
94 5 M 15 MTC - I/LCS BF - ↓ 1,2 IV - - DI 372 (18%) - - - III P I C 9
95 2 M 8 MTC - I/LN BF - ↓ 1,2 IV - - DI 890 (28%) - - - III P I T 9
96 9 M 18 MTC - I/LN BF - ↓ 1,2 IV - - HA 911 (25%) - - - III P I C 9
97 10 F 16 MTC - I/LN BF - ↓ 1,2 IV - - UZ 909 (20%) - - - III P I C 9
98 11 M 15 MTC - I/LN BF - ↓ 1,2,3 III + - M 31 (8%) - - - III P I D 9
99 11 F 12 MTC - I/LN BF + ↓ 1,2,3 IV - - MZ 84 (10%) - - - III P I C 9
100 9 F 15 MTC - I/LN BF + ↓ 1,2,3 III, VI - - - 180 (11%) - - CSF+ IV EP I C 9
Abbreviations to Master Chart:
MTC - Mother to Child System Examination USG Abdomen
BT - Blood Transmission I - Lymph Nodes HEP - Hepatomegaly
UK - Unknown II - Skin HSM - Hepatosplenomegaly
NVP - Nevirapine III- Oral Cavity N - Nodes
POD - Place of Delivery IV - Respiratory System Norm. - Normal
MOD - Mode of Delivery V - Abdomen A - Ascites
I/LN - Institution / Labour Naturalis VI - CNS, Others ATT
I/LCS - Institution / Lower Caesarean Section CXR P - Pulmonary
H/LN - Home / Labour Naturalis UZ - Upper Zone EP - Extra Pulmonary
BF - Breast Feed MZ - Middle Zone Rx Outcome
CM - Cow's Milk LZ - Lower Zone C - Cured
Mix - Mixed M - Miliary D - Death
Clinical Features PE - Pleural Effusion T - Transfer
1 - Fever HA - Hilar Adenopathy DF - Default
2 - Cough B - Bronchiectasis IR - Irregular
3 - Loss of appetite DI - Diffuse Infiltrates Ctx - Cotrimoxazole Prophylaxis
4 - Lymphadenopathy CS- Caries Spine
5 - Abdominal Pain FNAC
6 - Seizures, Back Pain, etc. + : Granulomatous changes
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PROFORMA 
TB MANIFESTATIONS IN PEDIATRIC HIV  
 Name :       
 Age / Sex:           
 Address: 
 
 Parent/Guardians Name & Address: 
 
 Date of Sero positivity :  
 Place of Sero positivity :  
 Mode of Transmission :  
a) Mother to child : 
b) Blood transfusion: 
c) Other modes (sexual, injection etc.,)  
d) Unknown 
 Mother ANC History :  HAART / NVP / NIL 
 Place of Delivery : Institution / Home 
 Mode of Delivery :  
a) Labour Naturalis:  
b) Caesarean section:  Elective / 
Emergency  
c) Vacuum  
d)  Assisted forceps:  
Infant feeding       Duration :  
a) Exclusive Breast feeding  
b) Artificial feeding  
c) Cow’s milk 
d) Mixed  
 Developmental Milestones : Normal / Abnormal 
 FAMILY HISTORY   
Members Age  / Sex 
HIV 
Status CD4 
On 
ART 
Y/N 
TB 
status 
Y/N 
On 
ATT 
Y/N 
Father 
Mother 
Brothers 
Sisters 
Others 
 
      
 
 
Socio Economic H of Parent/Guardian:  
Education Status: 
Illiterate  
Primary School 
Higher Secondary  
College  
 
Employed   :    Yes/No 
Occupation   :   
Per capita income   :    
Clinical Manifestations :    
Fever   : 
Cough  : 
Breathlessness : 
Loss of appetite : 
Abdominal Pain : 
Diarrhea  : 
Lymphadenopathy:   
ALOC/ Seizures/mental deterioration: 
Osteoarthritis  : 
Others   
General Examination Height:  Weight:  MAC:  BMI: 
Built: (well)  (moderate) (poor) 
(Febrile)  
 
(pallor)  ( cyanosis) (Tachypnoeic)  
 
(pedal edema) (Jaundice) (others) 
Lymph nodes:  Y/N (Region)   (Nos:) 
                              Cervical / Axillary / Others 
       (Tender/non tender)   (Matted/Discrete) 
Skin:   (Normal) (PPE) (IBA) (Scabies) (Herpes Zoster) 
         (Seb.derm) (Tinea) (xerosis) (others) 
Oral Cavity  (Normal) (Oral candidiasis) (OHL) (Hyper pigmentation)  
       (Aphthous ulcer) 
    (Herpes simplex) (Angular stomatitis) (others) 
 
RS: (normal) (breath sounds) (added sounds) (others) 
CVS: (Normal) (Abnormal) 
Abdomen: (Normal) (Tenderness) (Organomegaly) 
Genitals: Normal / Abnormal 
CNS:  (Normal) (Consciousness) (Neck stiffness) (plantar reflex) (DTR) 
 (Memory) (Motor weakness) (Sensory signs) (visual disturbance) 
Immunisation    H     : BCG / OPV 
Investigation        :  
 Hb%      : 
 TC     : 
 DC    : 
 ESR   :  
 Sugar   : 
 Urea    : 
 Creatinine  : 
 LFT    : 
      1.  
Sputum for AFB    2.  
 3. 
Mantoux test   : 
CXR     :  
CD 4 Count / CD 4 % : 
FNAC   : 
 USG Abdomen  : 
 CT Scan Brain  : 
CSF    :  
 Others    : 
Δ   : HIV C−  TB WHO Stage   I / II / III / IV  
 
TREATMENT HISTORY: 
        ATT 
                
         
 
 
        Pulmonary 
      Sputum +ve/-ve   
 
        Extra 
 pulmonary 
                       
         
 
 
                                I 
 
Category                II 
 
                               III 
• Date of Treatment  
      Started 
      Completed  
• Adherence 
      Regular / Irregular 
• Treatment outcome 
• Cure  
• Treatment completed 
• Treatment Failure 
• Default  
• Died  
• Transfer out 
Side Effects 
 
Re infection 
Relapse  
Recurrence  
Cotrimoxazole prophylaxis: Y / N Regular / Irregular 
ART  
Regimen :  ZLN / ZLE / SLE / SLN 
Date of treatment started: 
Adherence: Good / Poor / occasionally missed  
 Reasons for missing: 
Side Effects   
IRIS: 
 
